pulmonary fibrosis

Pulmonary fibrosis patients have long suffered through side effects from their drugs. That could change with the potential for new inhaled versions in clinical trials.

Synthetic control arms are emerging as a valuable solution for clinical trials where using traditional placebo groups is difficult, unethical, or impractical.

Qureight’s deep-learning image biomarkers and clinical data analytics platform used to analyse enrolled idiopathic pulmonary fibrosis (IPF) patient data, supporting efficacy outcome and expansion to larger global patient studies

Injecting lung stem cells into the bloodstream of mice with idiopathic pulmonary fibrosis improved their lung function, setting the stage for human trials.